A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Summary

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

Timeline

Start

2019-01-24

Primary completion

2025-12-31

Completion

2025-12-31

Outcome

Met primary endpoint

release “The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint” unither.com ↗

Drugs

Indications